ImmunityBio’s (IBRX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of ImmunityBio (NASDAQ:IBRX) in a research note issued to investors on Thursday morning,Benzinga reports. The firm currently has a $30.00 price objective on the stock.

A number of other equities analysts also recently issued reports on IBRX. Piper Sandler dropped their price target on ImmunityBio from $6.00 to $4.75 and set a “neutral” rating on the stock in a research report on Monday, August 19th. EF Hutton Acquisition Co. I raised shares of ImmunityBio to a “strong-buy” rating in a research report on Wednesday, October 23rd.

ImmunityBio Stock Performance

ImmunityBio stock opened at $5.24 on Thursday. The company has a market capitalization of $3.65 billion, a PE ratio of -5.54 and a beta of 0.99. The company has a 50 day moving average price of $4.27 and a 200-day moving average price of $5.15. ImmunityBio has a fifty-two week low of $3.10 and a fifty-two week high of $10.53.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Victory Capital Management Inc. lifted its stake in shares of ImmunityBio by 16.0% during the 2nd quarter. Victory Capital Management Inc. now owns 19,953 shares of the company’s stock worth $126,000 after purchasing an additional 2,746 shares during the last quarter. Wealth Effects LLC lifted its position in shares of ImmunityBio by 3.4% during the third quarter. Wealth Effects LLC now owns 90,500 shares of the company’s stock valued at $337,000 after buying an additional 3,000 shares during the last quarter. Exchange Traded Concepts LLC boosted its holdings in shares of ImmunityBio by 8.4% in the 3rd quarter. Exchange Traded Concepts LLC now owns 47,984 shares of the company’s stock valued at $178,000 after buying an additional 3,722 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of ImmunityBio by 3.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 123,879 shares of the company’s stock worth $667,000 after acquiring an additional 4,533 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of ImmunityBio by 22.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock valued at $99,000 after purchasing an additional 4,545 shares during the last quarter. 8.58% of the stock is currently owned by hedge funds and other institutional investors.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.